Trials are planned in several hospitals affiliated with the Leeds and Newcastle universities, lead by a lead surgeon in Leeds . The facility in Newcastle is Medicines and Healthcare products Regulatory Agency (MHRA) licensed and one of the biggest such facility in Europe. It’s a clean room complex designed specifically for cellular therapies production.
Betalin collaborates towards clinical application of the EMP1 product with leading surgeons, at Northwestern Memorial Hospital, a nationally ranked academic medical center. Through this collaboration, Betalin aims to perform pre-clinical studies within the GMP facilities, submit an IND, and upon approval to conduct clinical trials. High quality & fresh islet will be supplied by the in-house islet isolation centres. As part of the collaboration, the diabetes patients from the clinics will be targeted for the clinical trials which will take place at the hospital.
The collaboration with Technische Universitӓt Dresden includes R&D development of EMP1R and enables Betalin to gain access to the German and European market through their extensive academic and pharma network. In addition, the active Diabetes Center can be a potential clinical site for future clinical trials.
The collaboration with the Clinic for Endocrinology in USZ includes R&D development of EMP1R and enables Betalin to gain access to the Switzerland market through their extensive academic and pharma network
Kugelmeier have developed a patented platform technology that allows the creation of highly standardized cell spheroids. The collaboration includes R&D development of EMP1R and enables Betalin to gain access to the Switzerland market
The Diabetes Research Institute (DRI) at San Raffaele Hospital (OSR); research and strategic collaboration with Prof Lorenzo Piemonti, the director of the DRI on the Beta-EMP product. The DRI is a specialized Research Institute entirely devoted to diabetes, which aims to accelerate the development of novel therapies for diabetes as well as improving existing therapies